| Title |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab
|
|---|---|
| Published in |
Biologics: Targets & Therapy, January 2016
|
| DOI | 10.2147/btt.s60523 |
| Pubmed ID | |
| Authors |
Jean L Koff, Sagar Lonial |
| Abstract |
Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 20% |
| Student > Ph. D. Student | 3 | 20% |
| Other | 2 | 13% |
| Student > Doctoral Student | 2 | 13% |
| Lecturer | 1 | 7% |
| Other | 3 | 20% |
| Unknown | 1 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 53% |
| Nursing and Health Professions | 1 | 7% |
| Sports and Recreations | 1 | 7% |
| Agricultural and Biological Sciences | 1 | 7% |
| Social Sciences | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 2 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2016.
All research outputs
#22,938,588
of 25,576,801 outputs
Outputs from Biologics: Targets & Therapy
#236
of 274 outputs
Outputs of similar age
#343,036
of 400,833 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 4 outputs
Altmetric has tracked 25,576,801 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,833 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.